Highly potent and selective HIF-1α
= 29.4 pM). Selectively inhibits HIF-1 binding to the VEGF promoter without affecting the binding of AP-1 or NF-κ
B. Inhibits colony formation of cancer stem cells (CSC) with a 100-fold selectivity over normal hematopoietic progenitor cells. Eradicates mouse lymphomas and human AML xenografts by eliminating CSCs.
Soluble to 5 mM in DMSO
Store at -20°C
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity.
Kong D, Park EJ, Stephen AG et al.
Cancer Res. 65(19):9047-55.
Targeting HIF1α eliminates cancer stem cells in hematological malignancies.
Wang et al.
Cell Stem Cell, 2011;8:399
Physical and functional interactions between Runx2 and HIF-1α induce vascular endothelial growth factor gene expression.
Kwon et al.